Drug Profile
Autogene cevumeran - Genentech
Alternative Names: BNT-122; BNT122/RO7198457; Individualized Neoantigen Specific immunotherapy; iNeST; IVAC_M_uID; PCV RO7198457; Personalized cancer vaccine RO7198457; RG-6180; RG6180-1; RO-7198457Latest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator BioNTech
- Developer BioNTech; Genentech; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma; Colorectal cancer; Malignant melanoma
- Phase I Pancreatic cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 07 Apr 2024 Pharmacodynamics and efficacy data from a phase I trial in Pancreatic cancer released by BioNTech
- 20 Mar 2024 BioNTech plans an additional phase II trial in as early as 2024
- 22 Jul 2023 Phase-II clinical trials in Adenocarcinoma (Adjuvant therapy, Combination therapy) in USA (IV) (NCT05968326)